hSCN9A Mouse

The SCN9A gene encodes the sodium channel protein Nav1.7 and is closely associated with peripheral neuropathic pain and several related rare genetic disorders. The Nav1.7 sodium channel mediates the flow of sodium ions across the cell membrane and plays an important role in the generation and transmission of electrical signals in neurons. Studies have shown that genetic variants in SCN9A are closely associated with several inherited pain disorders, including inherited erythromelalgia (IEM), small fiber neuropathy (SFN), and congenital insensitivity to pain (CIP) ^[1-2]. As a voltage-gated sodium channel, Nav1.7 is mainly expressed in sensory and sympathetic neurons of the peripheral nervous system and is highly expressed in the dorsal root ganglia (DRG), where it plays a critical role in the generation and transmission of pain signals ^[3]. Studies have suggested that downregulation of SCN9A expression or selective inhibition of Nav1.7 may represent a potential analgesic strategy for investigating acute, inflammatory, and neuropathic pain ^[4].

The hSCN9A Mouse is a humanized Scn9a model. The coding sequences of exon 2 plus partial intron 2 of mouse Scn9a were replaced with the Kozak-Human SCN9A CDS-3'UTR of Human SCN9A-WPRE-BGH pA cassette. Its applications mainly include mechanistic studies of inherited erythromelalgia (IEM), small fiber neuropathy (SFN), congenital insensitivity to pain (CIP), and SCN9A-associated epileptic encephalopathies, as well as the exploration of therapeutic strategies targeting human Nav1.7. This model may be used to evaluate the potential effects of Nav1.7 inhibitors, antisense nucleic acid-based approaches, and gene therapies and to support drug screening and pharmacological evaluation for SCN9A-related disorders.